← Back to newsBODYPORT / NEWS & RESEARCH

June 23, 2022

Wearables are collecting a flood of data. An ambitious new study of pregnancy aims to prove that’s valuable for health

We are excited about our collaboration with 4YouAndMe for the BUMP study, measuring changes in heart function and fluid status during pregnancy. Read more here.

← All news and announcements Clinical evidence →

About Bodyport

Bodyport develops remote monitoring technologies for patients with fluid management-related health conditions. The FDA-cleared Bodyport Cardiac Scale measures weight, peripheral impedance, pulse rate, and balance through a simple daily measurement. Bodyport’s clinician-facing software combines longitudinal data into the Congestion Index, a clinical decision support tool that helps healthcare professionals identify and evaluate changes associated with worsening congestion. Based in San Francisco, the company is backed by top-tier investors including Boehringer Ingelheim Venture Fund, Terumo Medical, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.